Tenaya Therapeutics Announces Pricing of Public Offering

Core Viewpoint - Tenaya Therapeutics, Inc. has announced a public offering of 75,000,000 units, aiming to raise approximately $52.5 million to support its clinical development and general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of 75,000,000 units priced at$0.70 per unit, each unit includes one share of common stock and two types of warrants [3]. - The warrants include a Series A Warrant for one share at an exercise price of $0.80, and a Series B Warrant for half a share at an exercise price of$0.70, both immediately exercisable [3]. - The offering is expected to close around March 5, 2025, pending customary closing conditions [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the ongoing and planned development of clinical and early-stage product candidates, particularly TN-201 and TN-401, along with working capital and other general corporate purposes [2]. Group 3: Company Overview - Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing potentially curative therapies for heart disease, employing integrated capabilities for genetic medicine development [8]. - The company's pipeline includes TN-201 for MYBPC3-associated hypertrophic cardiomyopathy, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, and TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction [8].